FDA approves new drug for thrombocytopenia in patients with chronic liver disease

Author(s):

drug thrombocytopenia liver disease

On May 21, the U.S. Food and Drug Administration (FDA) approved approved Doptelet (avatrombopag) tablets to treat thrombocytopenia in adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.

Read more via FDA.gov.

LEAVE A REPLY

Please enter your comment!
Please enter your name here